Company / Financials
ENDONOVO THERAPEUTICS, INC. Financials
FY2011-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$135.4K
FY2022 · +85.2% YoY
Net Income
-$18.5M
FY2022 · -495.0% YoY
Profit Margin
-13649.2%
FY2022 · net income / revenue
ROE
-
FY2022 · return on equity
Total Assets
$1.3M
FY2022
Total Debt
$7.2M
-0.22x debt/equity
Equity
-$32.2M
FY2022
ROA
-1441.9%
FY2022 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$135.4K+85.2% YoYNet Income HistoryProfit after all expenses and taxes-$18.5M-495.0% YoYGross Profit HistoryRevenue minus cost of goods sold$125.4K+115.7% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$10.0K-33.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$3.3M-46.6% YoYR&D Expense HistoryResearch and development spending-Interest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-EPS (Basic) HistoryBasic earnings per share-$0.05EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-